Some Scientists Aren’t So Sure A Coronavirus Vaccine Will Come To The Rescue.
Pandemic-weary residents everywhere are holding their breath for the first coronavirus vaccines to be approved by federal regulators. The shots, currently being mass produced...
Hepion Pharma Doses First Patient in the ‘AMBITION’ Clinical Trial.
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH.
(A lot of big words below,...
Adding Hepion Pharma (HEPA) $1.73 to Watch List.
Adding Hepion Pharma ($1.73) to Watch List. Oh My. What Did We Find Here?
Oh my…and Oh boy. We just signed a new client and...
Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3. BioSig (BSGM) $4.70. We're Up 60%,...
Dalrada (DFCO) Appoints Gregory L. Remsen To Vice President of Strategic Relationships.
Dalrada Financial Corporation Appoints Gregory L. Remsen To Vice President of Strategic Relationships
DALRADA NEWS ARCHIVE
SAN DIEGO , Dec. 8, 2020 /PRNewswire/ -- Dalrada Financial Corp. (OTC Pink: DFCO) announces...
Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.
Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression...
Dalrada (DFCO) Finally Pops. Up 59% Today.
Up 59% today on news and with 4 million shares trading and counting!
LIVE QUOTE
Adding Dalrada (DFCO) $0.09 to CoronaVirus Stock Watch List.
With small and...
Adding Hapbee (HAPB) to the Watch List.
Listed on TSX under HAPB, we're officially price and time stamping our interest in this amazing little technology Company by adding it to our...
Hapbee’s (HAPB) Device, “Choose How You Feel.”
HAPBEE ANNOUNCES LAUNCH OF A SUBSCRIPTION-BASED WELLBEING WEARABLE, PROVIDING MEMBERS THE ABILITY TO CHOOSE 'HOW THEY FEEL'
Proprietary, Research-Backed Band Delivers Control and Peace of...
Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected catheter."
LIVE QUOTE
Citius...